Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation Alone in Patients With Aggressive B-cell Lymphoma: NHL-13

NCT00400478 is registered in ClinicalTrials.gov with Arbeitsgemeinschaft medikamentoese Tumortherapie as lead sponsor.

NCT NCT00400478
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00400478 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation Alone in Patients With Aggressive B-cell Lymphoma: NHL-13
Lead sponsor
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2006
Completion date
March 31, 2013
Enrollment
683 (actual)
Sites
131

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma (dlbcl), follicular nhl grade 3b